For many years, risk stratification has served as one of the most important tools in our efforts to lower the incidence of cardiovascular disease. Yet our tools are by no means perfect, and thus there is room for improvement. How do we move past the limitations of current biomarkers, imaging and genetic tests, enhancing our capacity to perform more accurate risk assessments? Dr. Vijay Nambi, assistant professor of medicine in the section of atherosclerosis and vascular medicine at Baylor College of Medicine, joins host Dr. Larry Kaskel to talk about a range of issues in risk stratification. How is risk scoring impacted by risk factors versus risk markers? When are 10-year risk measurements preferred over lifetime risk figures?
Brought to you by:
